Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K current report with the SEC on April 27, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). Ligand to acquire XOMA Royalty for $39.00 cash per common share plus contingent value rights tied to RemainCo LLC assets.
LIGAND PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Ligand to acquire XOMA Royalty for $39.00 cash per common share plus contingent value rights tied to RemainCo LLC assets
- Preferred stock treatment includes conversion of Series X shares and redemption of Series A and Series B shares plus accrued dividends
- Supporting stockholders representing approximately 47% of outstanding shares agreed to vote for the transaction, materially improving approval certainty
- Closing requires stockholder approval, antitrust clearance, Holding Company Reorganization and CVR Spin, with no financing condition
- $40 million termination fee applies to XOMA Royalty under specified competing-bid or adverse-recommendation scenarios; outside closing date January 26, 2027
Item 8.01 · Other Events
- Ligand and XOMA Royalty executed a merger agreement on April 27, 2026, initiating a proposed acquisition requiring XOMA stockholder approval
- Investor presentation and joint announcement accompany the transaction, signaling formal deal launch and forthcoming proxy materials
- Closing remains contingent on regulatory approvals and XOMA stockholder approval, creating execution and timing risk
- Key risks include competing offers, integration challenges, transaction costs, litigation, and failure to realize expected acquisition benefits
Item EX-99.1 · Exhibit EX-99.2
- Ligand to acquire XOMA Royalty for $39 per share cash, approximately $739 million equity value, funded with cash and credit-facility borrowings
- Portfolio expands by over 120 assets, seven commercial products, and 14 late-stage programs, increasing diversification across ophthalmology, oncology, CNS, and rare diseases
- 2026 revenue guidance raised to $270–$310 million from $245–$285 million, with royalty revenue raised to $225–$250 million
- 2026 adjusted EPS guidance increased to $8.50–$9.50 from $8.00–$9.00; transaction expected to add $1.50 per share in 2027
- Closing targeted for third quarter 2026, subject to XOMA stockholder approval, regulatory approvals, and customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIGAND PHARMACEUTICALS INC 8-K filings
Get the next LGND 8-K as it lands
Follow LGND for push alerts, or ask the research agent what this filing means.